These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 38698698)
1. Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study). Kinos S; Hagman H; Halonen P; Soveri LM; O'Reilly M; Pfeiffer P; Frödin JE; Sorbye H; Heervä E; Liposits G; Kallio R; Ålgars A; Ristamäki R; Salminen T; Bärlund M; Shah CH; McDermott R; Röckert R; Flygare P; Kwakman J; Teske A; Punt C; Glimelius B; Österlund P Acta Oncol; 2024 May; 63():248-258. PubMed ID: 38698698 [TBL] [Abstract][Full Text] [Related]
2. Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review. Winther SB; Zubcevic K; Qvortrup C; Vestermark LW; Jensen HA; Krogh M; Sorbye H; Pfeiffer P; Acta Oncol; 2016 Jul; 55(7):881-5. PubMed ID: 27181284 [TBL] [Abstract][Full Text] [Related]
3. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial. Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411 [TBL] [Abstract][Full Text] [Related]
4. Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study. Nakayama G; Kodera Y; Yokoyama H; Okuda N; Watanabe T; Tanaka C; Iwata N; Ohashi N; Koike M; Fujiwara M; Nakao A Int J Clin Oncol; 2011 Oct; 16(5):506-11. PubMed ID: 21431344 [TBL] [Abstract][Full Text] [Related]
5. Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer. Franck C; Malfertheiner P; Venerito M BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28536214 [TBL] [Abstract][Full Text] [Related]
6. Comparison of efficacy and safety of S-1 and capecitabine in patients with metastatic colorectal carcinoma: A systematic review and meta-analysis. Chen J; Wang J; Xu T Medicine (Baltimore); 2019 Jul; 98(30):e16667. PubMed ID: 31348323 [TBL] [Abstract][Full Text] [Related]
7. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study. Osterlund P; Kinos S; Pfeiffer P; Salminen T; Kwakman JJM; Frödin JE; Shah CH; Sorbye H; Ristamäki R; Halonen P; Soveri LM; Heervä E; Ålgars A; Bärlund M; Hagman H; McDermott R; O'Reilly M; Röckert R; Liposits G; Kallio R; Flygare P; Teske AJ; van Werkhoven E; Punt CJA; Glimelius B ESMO Open; 2022 Jun; 7(3):100427. PubMed ID: 35798468 [TBL] [Abstract][Full Text] [Related]
8. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232 [TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin. Yasui H; Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamazaki K; Taku K; Kojima T; Machida N Jpn J Clin Oncol; 2009 May; 39(5):315-20. PubMed ID: 19403734 [TBL] [Abstract][Full Text] [Related]
12. Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. Yamada Y; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Kato K; Hamaguchi T; Shimada Y Invest New Drugs; 2012 Aug; 30(4):1690-6. PubMed ID: 21894500 [TBL] [Abstract][Full Text] [Related]
13. A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer. Yamaguchi K; Taniguchi H; Komori A; Narita Y; Nitta S; Nomura M; Kadowaki S; Takahari D; Ura T; Andoh M; Muro K; Mori K; Igarashi Y BMC Cancer; 2015 Aug; 15():601. PubMed ID: 26311588 [TBL] [Abstract][Full Text] [Related]
14. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966 [TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial). Yoshida M; Muro K; Tsuji A; Hamamoto Y; Yoshino T; Yoshida K; Shirao K; Miyata Y; Takahari D; Takahashi T; Ohtsu A Eur J Cancer; 2015 May; 51(8):935-41. PubMed ID: 25837882 [TBL] [Abstract][Full Text] [Related]
16. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. Winther SB; Österlund P; Berglund Å; Glimelius B; Qvortrup C; Sorbye H; Pfeiffer P; BMC Cancer; 2017 Aug; 17(1):548. PubMed ID: 28814275 [TBL] [Abstract][Full Text] [Related]
17. Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group. Kwakman JJM; van Werkhoven E; Simkens LHJ; van Rooijen JM; van de Wouw YAJ; Tije AJT; Creemers GM; Hendriks MP; Los M; van Alphen RJ; Polée MB; Muller EW; van der Velden AMT; van Voorthuizen T; Koopman M; Mol L; Punt CJA Clin Colorectal Cancer; 2019 Jun; 18(2):e229-e230. PubMed ID: 30782413 [No Abstract] [Full Text] [Related]
18. A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer. Yamazaki K; Kuwano H; Ojima H; Otsuji T; Kato T; Shimada K; Hyodo I; Nishina T; Shirao K; Esaki T; Ohishi T; Denda T; Takeuchi M; Boku N Cancer Chemother Pharmacol; 2015 Mar; 75(3):569-77. PubMed ID: 25575764 [TBL] [Abstract][Full Text] [Related]
19. Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer. Punt CJA; Heinemann V; Maughan T; Cremolini C; Van Cutsem E; McDermott R; Bodoky G; André T; Osterlund P; Teske AJ; Pfeiffer P ESMO Open; 2023 Apr; 8(2):101199. PubMed ID: 37018874 [TBL] [Abstract][Full Text] [Related]
20. A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. Lee J; Shin SJ; Chung IJ; Kim TW; Chun HG; Shin DB; Kim YH; Song HS; Han SW; Kim JG; Kim SY; Choi YJ; Chung HC Invest New Drugs; 2014 Jun; 32(3):561-8. PubMed ID: 24573743 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]